SBT Ultrasonic Technology Co Ltd (688392)

Currency in CNY
86.76
+2.89(+3.45%)
Delayed Data·
688392 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
Fair Value
Day's Range
83.7092.18
52 wk Range
27.7892.18
Key Statistics
Bid/Ask
86.76 / 86.80
Prev. Close
83.87
Open
85.55
Day's Range
83.7-92.18
52 wk Range
27.78-92.18
Volume
2.65M
Average Volume (3m)
2.33M
1-Year Change
160.94%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688392 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.04
Downside
-69.99%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

SBT Ultrasonic Technology Co Ltd Company Profile

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Compare 688392 to Peers and Sector

Metrics to compare
688392
Peers
Sector
Relationship
P/E Ratio
−123.3x−16.3x−0.5x
PEG Ratio
−5.370.570.00
Price/Book
5.1x7.0x2.6x
Price / LTM Sales
28.2x16.7x3.3x
Upside (Analyst Target)
−71.5%5.0%42.8%
Fair Value Upside
Unlock−13.7%6.5%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 26.04
(-69.99% Downside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
381.26M / --
EPS Revisions
Last 90 days

688392 Income Statement

FAQ

What Stock Exchange Does SBT Ultrasonic Tech Trade On?

SBT Ultrasonic Tech is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for SBT Ultrasonic Tech?

The stock symbol for SBT Ultrasonic Tech is "688392."

What Is the SBT Ultrasonic Tech Market Cap?

As of today, SBT Ultrasonic Tech market cap is 34.59B.

What Is SBT Ultrasonic Tech's Earnings Per Share (TTM)?

The SBT Ultrasonic Tech EPS (TTM) is -0.17.

When Is the Next SBT Ultrasonic Tech Earnings Date?

SBT Ultrasonic Tech will release its next earnings report on 18 Aug 2025.

From a Technical Analysis Perspective, Is 688392 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has SBT Ultrasonic Tech Stock Split?

SBT Ultrasonic Tech has split 0 times.

How Many Employees Does SBT Ultrasonic Tech Have?

SBT Ultrasonic Tech has 1089 employees.

What is the current trading status of SBT Ultrasonic Tech (688392)?

As of 06 Aug 2025, SBT Ultrasonic Tech (688392) is trading at a price of 86.76, with a previous close of 83.87. The stock has fluctuated within a day range of 83.70 to 92.18, while its 52-week range spans from 27.78 to 92.18.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.